AC Immune director granted shares and options

AC Immune SA director Roy Ervin Twyman received equity awards as compensation.

Rhea-AI Filing Summary

AC Immune SA director Roy Ervin Twyman received equity awards as compensation. On June 11, 2026 he was granted 16,568 restricted share units under the AC Immune SA 2016 Stock Option and Incentive Plan, increasing his holdings to 92,556 common shares, including 66,556 shares underlying outstanding restricted share units.

On the same date he also received share options over 38,889 common shares with an exercise price of $2.62 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036, giving him the right to buy the underlying shares in the future rather than reflecting an open-market purchase.

Insider Trade Summary

Grant/Award: 55,457 shares

Grant/Award 2 txns

Insider Twyman Roy Ervin

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy)	38,889	$0.00	$0.00
Grant/Award	Common Share	16,568	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 38,889 contracts (Direct); Common Share — 92,556 shares (Direct)

Footnotes (3)

1. F1. On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP).
2. F2. Includes 66,556 common shares underlying outstanding restricted share units.
3. F3. On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027.

Key Figures

RSU grant: 16,568 units Options granted: 38,889 options Option exercise price: $2.62 per share +4 more

7 metrics

RSU grant 16,568 units Restricted share units granted on June 11, 2026

Options granted 38,889 options Share options granted on June 11, 2026

Option exercise price $2.62 per share Exercise price for 38,889 share options

Option vesting date June 10, 2027 Date options will fully vest

Option expiration date June 10, 2036 Expiration of 38,889 share options

Shares after transaction 92,556 shares Common shares beneficially held after June 11, 2026 grants

RSUs included in holdings 66,556 shares Common shares underlying outstanding RSUs included in total holdings

Key Terms

restricted share unit, Share Option (right to buy), 2016 Stock Option and Incentive Plan (SOIP), exercise price, +1 more

5 terms

restricted share unit financial

"received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan"

A restricted share unit (RSU) is a promise by a company to give an employee a set number of company shares at a future date, typically after meeting time or performance conditions. For investors, RSUs matter because when they convert into actual shares they increase the number of shares outstanding (like unlocking more tickets in a game), which can dilute existing holders, and they align employee incentives with company performance, influencing behavior and long-term value.

Share Option (right to buy) financial

"security_title": "Share Option (right to buy)""

2016 Stock Option and Incentive Plan (SOIP) financial

"under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP)"

exercise price financial

"conversion_or_exercise_price": "2.6200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The share options will fully vest on June 10, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did AC Immune (ACIU) director Roy Ervin Twyman report?

AC Immune director Roy Ervin Twyman reported receiving equity compensation, including 16,568 restricted share units and options on 38,889 shares. These awards were granted under the company’s 2016 Stock Option and Incentive Plan on June 11, 2026 and did not involve open-market buying or selling.

How many AC Immune (ACIU) shares does Roy Ervin Twyman hold after this Form 4?

After the reported grants, Roy Ervin Twyman beneficially holds 92,556 common shares of AC Immune. This total includes 66,556 common shares underlying outstanding restricted share units, reflecting his combined direct and RSU-based equity exposure following the June 11, 2026 awards.

What are the key terms of Roy Ervin Twyman’s new AC Immune (ACIU) stock options?

Roy Ervin Twyman received share options over 38,889 AC Immune common shares with a $2.62 exercise price. These options were granted on June 11, 2026, will fully vest on June 10, 2027, and are scheduled to expire on June 10, 2036 if not exercised.

Is Roy Ervin Twyman buying or selling AC Immune (ACIU) stock in this Form 4?

The Form 4 reflects equity awards, not open-market trading. Roy Ervin Twyman acquired 16,568 restricted share units and 38,889 share options as compensation. No purchases or sales of AC Immune shares in the market are reported in this filing.

What equity compensation plan does AC Immune (ACIU) use for Roy Ervin Twyman’s awards?

Roy Ervin Twyman’s restricted share units and share options were granted under the AC Immune SA 2016 Stock Option and Incentive Plan. This plan provides for restricted share units and options as part of the company’s long-term equity-based compensation for directors and other eligible participants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 07:10 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Twyman Roy Ervin

(Last) (First) (Middle)

EPFL INNOVATION PARK, BUILDING B

(Street)

LAUSANNE 1015

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
AC Immune SA [ ACIU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Share	06/11/2026		A		16,568(1)	A	$0(2)	92,556	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$2.62	06/11/2026		A		38,889		06/10/2027(3)	06/10/2036	Common Share	38,889	$0	38,889	D

Explanation of Responses:

1. On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP).

2. Includes 66,556 common shares underlying outstanding restricted share units.

3. On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027.

	Matthias Maurer as Attorney-in-Fact for Roy Twyman	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)